Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin add-on to sitagliptin in type 2 diabetes
NCT00984867Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2009
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Oct 2009; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00984867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00984867.